Infections, Rotavirus Clinical Trial
Official title:
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Verified date | July 2020 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus (HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose vaccination in healthy infants starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the study.
Status | Completed |
Enrollment | 1612 |
Est. completion date | November 26, 2018 |
Est. primary completion date | June 27, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Weeks to 12 Weeks |
Eligibility |
Inclusion Criteria: - Subjects' parent(s)/LAR(s) who, in the opinion of the investigator can and will comply with the requirements of the protocol. - Written informed consent obtained from the parent(s)/LAR(s) (Legally acceptable representatives) of the subject prior to performing any study specific procedure. - A male or female infant between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination. - Born full-term (i.e., between a gestation period of 37 weeks 0 days and 41 weeks 6 days). - Healthy subjects as established by medical history and clinical examination before entering into the study. Exclusion Criteria: - Child in care - Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines (Day-29 to Day 0), or planned use during the study period. - Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone (0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed. - Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. - Administration of long-acting immune-modifying drugs at any time during the study period. - Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose of vaccine administration and ending at Visit 3, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study and other licensed routine childhood vaccinations. - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. - Uncorrected congenital malformation of the gastrointestinal tract that would predispose for Intussusception (IS). - History of IS. - Family history of congenital or hereditary immunodeficiency. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. - Major congenital defects or serious chronic illness. - Previous vaccination against RV. - Previous confirmed occurrence of RVGE. - GE within 7 days preceding the study vaccine administration. - History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. - Hypersensitivity to latex. - Acute disease and/or fever at the time of enrolment. - Fever is defined as temperature =38.0°C/100.4°F. The preferred location for measuring temperature in this study will be the oral cavity, the axilla and the rectum. - Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. |
Country | Name | City | State |
---|---|---|---|
Costa Rica | GSK Investigational Site | San Jose | San José |
Costa Rica | GSK Investigational Site | San José | |
Finland | GSK Investigational Site | Espoo | |
Finland | GSK Investigational Site | Helsinki | |
Finland | GSK Investigational Site | Helsinki | |
Finland | GSK Investigational Site | Jarvenpaa | |
Finland | GSK Investigational Site | Kokkola | |
Finland | GSK Investigational Site | Oulu | |
Finland | GSK Investigational Site | Pori | |
Finland | GSK Investigational Site | Seinajoki | |
Finland | GSK Investigational Site | Tampere | |
Finland | GSK Investigational Site | Turku | |
Germany | GSK Investigational Site | Bramsche | |
Germany | GSK Investigational Site | Frankenthal | Rheinland-Pfalz |
Germany | GSK Investigational Site | Goch | Nordrhein-Westfalen |
Germany | GSK Investigational Site | Mannheim | Baden-Wuerttemberg |
Germany | GSK Investigational Site | Schoenau Am Koenigssee | Bayern |
Germany | GSK Investigational Site | Tauberbischofsheim | Baden-Wuerttemberg |
Japan | GSK Investigational Site | Chiba | |
Japan | GSK Investigational Site | Chiba | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Korea, Republic of | GSK Investigational Site | Gangwon-do | |
Korea, Republic of | GSK Investigational Site | Gyeonggido | |
Korea, Republic of | GSK Investigational Site | Incheon | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Spain | GSK Investigational Site | Antequera/Málaga | |
Spain | GSK Investigational Site | Castellón | |
Spain | GSK Investigational Site | Castellón | |
Spain | GSK Investigational Site | Madrid | |
Spain | GSK Investigational Site | Malaga | Andalucia |
Spain | GSK Investigational Site | Marbella | |
Spain | GSK Investigational Site | Sevilla | |
Spain | GSK Investigational Site | Valencia | |
Spain | GSK Investigational Site | Valencia | |
Spain | GSK Investigational Site | Valencia | |
Taiwan | GSK Investigational Site | Hsinchu | |
Taiwan | GSK Investigational Site | Taichung | |
Taiwan | GSK Investigational Site | Taichung | |
Taiwan | GSK Investigational Site | Taipei | |
Taiwan | GSK Investigational Site | Taipei | |
Taiwan | GSK Investigational Site | Taoyuan | |
United States | GSK Investigational Site | Anaheim | California |
United States | GSK Investigational Site | Birmingham | Alabama |
United States | GSK Investigational Site | Cheraw | South Carolina |
United States | GSK Investigational Site | Cleveland | Ohio |
United States | GSK Investigational Site | Erie | Pennsylvania |
United States | GSK Investigational Site | Kansas City | Missouri |
United States | GSK Investigational Site | Layton | Utah |
United States | GSK Investigational Site | Marshfield | Wisconsin |
United States | GSK Investigational Site | Murray | Utah |
United States | GSK Investigational Site | Nampa | Idaho |
United States | GSK Investigational Site | Newton | Kansas |
United States | GSK Investigational Site | North Charleston | South Carolina |
United States | GSK Investigational Site | Orem | Utah |
United States | GSK Investigational Site | Paramount | California |
United States | GSK Investigational Site | Provo | Utah |
United States | GSK Investigational Site | Sacramento | California |
United States | GSK Investigational Site | San Jose | California |
United States | GSK Investigational Site | Syracuse | Utah |
United States | GSK Investigational Site | Topeka | Kansas |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States, Costa Rica, Finland, Germany, Japan, Korea, Republic of, Spain, Taiwan,
Salamanca de la Cueva I, Pahud B, Huang LM, Leonardi M, Garcia-Sicilia J, Céspedes J, Abdelnour A, Tamura T, Kuroki H, Chiu NC, Virta M, Kokko S, Horn M, Panzer F, Kim JH, Jin L, Moerman L, Debacq C, Parra J, Ugarte A, Bi D; Rota-081 Study Group. Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial. J Infect Dis. 2020 May 4. pii: jiaa210. doi: 10.1093/infdis/jiaa210. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C) | Antibody concentrations against Rota Virus (RV) were determined as Geometric Mean Antibody Concentration (GMC) and expressed as Units per milliliter (U/mL). | At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Primary | Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value in Porcine Circovirus (PCV) -Free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Control Group | Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (<) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (=) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA). For this outcome measure, the three groups (Liq_A, Liq_B & Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of seroconversion rates of 1-2 months after Dose 2. |
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Primary | Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to 20 U/mL in Porcine Circovirus (PCV)-Free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group | Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (<) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (=) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA). The analysis was assessed to demonstrate the immunogenicity of PCV-free liquid HRV vaccine as compared to the currently licensed lyophilised HRV vaccine (individual HRV liquid groups) in terms of seroconversion rates 1-2 months after Dose 2. |
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Primary | Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Lyophilised Control Group | Antibody concentrations against RV were determined as GMCs and expressed as U/mL. For this outcome measure, the three groups (Liq_A, Liq_B & Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of antibody concentrations at 1-2 months after Dose 2. |
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Primary | Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group | Antibody concentrations against RV were determined as GMCs and expressed as U/mL. The analysis was assessed to demonstrate the immunogenicity of the PCV-free liquid HRV vaccine (individual HRV liquid groups) to that of the currently licensed lyophilised HRV vaccine in terms of serum anti-RV IgA antibody concentrations 1-2 months after Dose 2. | At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Secondary | Percentage of Subjects With Anti-RV IgA Concentrations (Pooled HRV Liquid Group) | Antibody concentrations =90 U/mL were determined and expressed as GMCs, assessed for the pooled HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations. For this outcome measure, the three groups (Liq_A, Liq_B & Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunogenicity of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of percentage of subjects with anti-RV IgA antibody concentrations = 90 U/mL, 1-2 months after Dose 2 |
At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Secondary | Percentage of Subjects With Anti-RV IgA Concentrations (Individual HRV Liquid Groups) | Antibody concentrations =90 U/mL were determined and expressed as GMCs, assessed for the individual HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations. The analysis was performed to assess the immunogenicity of the PCV-free liquid HRV vaccine (pooled HRV liquid groups) and the currently licensed lyophilised HRV vaccine, in terms of percentage of subjects with anti-RV IgA antibody concentrations = 90 U/mL 1-2 months after Dose 2. | At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries) | |
Secondary | Number of Subjects With Any Solicited General Adverse Events (AEs). | Assessed solicited general AEs were cough/runny nose, diarrhea, fever (defined as temperature = 38.0°C), irritability/fussiness, loss of appetite and vomiting. Any solicited general AE is defined as any occurrence of the specified symptom, irrespective of intensity grade and relationship to vaccination. | During the 8 days (Day 1 to Day 8) follow-up period after each dose of HRV vaccine | |
Secondary | Number of Subjects With Any Unsolicited AEs. | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination. | During the 31 day (Day 1 to Day 31) follow-up period after HRV vaccination across doses | |
Secondary | Number of Subjects With Any Serious Adverse Events (SAEs) | SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity. | During the entire study period (Day 1 to Month 7-8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01435967 -
Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™
|
N/A | |
Completed |
NCT00370318 -
Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines
|
Phase 3 | |
Completed |
NCT00345956 -
To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)
|
Phase 3 | |
Completed |
NCT00140686 -
To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines
|
Phase 3 | |
Completed |
NCT00383903 -
Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa
|
Phase 2 | |
Completed |
NCT00750893 -
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
|
||
Completed |
NCT00533507 -
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age
|
Phase 3 | |
Completed |
NCT00363545 -
To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)
|
Phase 3 | |
Completed |
NCT00489567 -
Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden
|
N/A | |
Completed |
NCT01733862 -
Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
|
||
Completed |
NCT00779779 -
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
|
||
Completed |
NCT00382772 -
A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).
|
Phase 3 | |
Completed |
NCT00729001 -
Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.
|
Phase 2 | |
Completed |
NCT00353366 -
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
|
||
Completed |
NCT01198769 -
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
|
Phase 4 | |
Completed |
NCT00385320 -
Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months
|
Phase 2 | |
Completed |
NCT00432380 -
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
|
Phase 2 | |
Completed |
NCT01563159 -
Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011
|
N/A | |
Completed |
NCT01339221 -
Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium
|
N/A | |
Completed |
NCT00653198 -
Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama
|
N/A |